Novel Biomarkers and Advanced Cardiac Imaging in Aortic Stenosis: Old and New
Currently, the symptomatic status and left ventricular ejection fraction (LVEF) play a crucial role in aortic stenosis (AS) assessment. However, the symptoms are often subjective, and LVEF is not a sensitive marker of left ventricle (LV) decompensation. Over the past years, the cardiac structure and...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-11-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/13/11/1661 |
| _version_ | 1827640406597173248 |
|---|---|
| author | Anca Drăgan Anca Doina Mateescu |
| author_facet | Anca Drăgan Anca Doina Mateescu |
| author_sort | Anca Drăgan |
| collection | DOAJ |
| description | Currently, the symptomatic status and left ventricular ejection fraction (LVEF) play a crucial role in aortic stenosis (AS) assessment. However, the symptoms are often subjective, and LVEF is not a sensitive marker of left ventricle (LV) decompensation. Over the past years, the cardiac structure and function research on AS has increased due to advanced imaging modalities and potential therapies. New imaging parameters emerged as predictors of disease progression in AS. LV global longitudinal strain has proved useful for risk stratification in asymptomatic severe AS patients with preserved LVEF. The assessment of myocardial fibrosis by cardiac magnetic resonance is the most studied application and offers prognostic information on AS. Moreover, the usage of biomarkers in AS as objective measures of LV decompensation has recently gained more interest. The present review focuses on the transition from compensatory LV hypertrophy (H) to LV dysfunction and the biomarkers associated with myocardial wall stress, fibrosis, and myocyte death. Moreover, we discuss the potential impact of non-invasive imaging parameters for optimizing the timing of aortic valve replacement and provide insight into novel biomarkers for possible prognostic use in AS. However, data from randomized clinical trials are necessary to define their utility in daily practice. |
| first_indexed | 2024-03-09T16:58:19Z |
| format | Article |
| id | doaj.art-16e0d417690a4aec9c9368ce29afd5ca |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-09T16:58:19Z |
| publishDate | 2023-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-16e0d417690a4aec9c9368ce29afd5ca2023-11-24T14:32:10ZengMDPI AGBiomolecules2218-273X2023-11-011311166110.3390/biom13111661Novel Biomarkers and Advanced Cardiac Imaging in Aortic Stenosis: Old and NewAnca Drăgan0Anca Doina Mateescu1Department of Cardiovascular Anaesthesiology and Intensive Care, Emergency Institute for Cardiovascular Diseases “Prof Dr C C Iliescu”, 258 Fundeni Road, 022328 Bucharest, RomaniaDepartment of Cardiology, Emergency Institute for Cardiovascular Diseases “Prof Dr C C Iliescu”, 258 Fundeni Road, 022328 Bucharest, RomaniaCurrently, the symptomatic status and left ventricular ejection fraction (LVEF) play a crucial role in aortic stenosis (AS) assessment. However, the symptoms are often subjective, and LVEF is not a sensitive marker of left ventricle (LV) decompensation. Over the past years, the cardiac structure and function research on AS has increased due to advanced imaging modalities and potential therapies. New imaging parameters emerged as predictors of disease progression in AS. LV global longitudinal strain has proved useful for risk stratification in asymptomatic severe AS patients with preserved LVEF. The assessment of myocardial fibrosis by cardiac magnetic resonance is the most studied application and offers prognostic information on AS. Moreover, the usage of biomarkers in AS as objective measures of LV decompensation has recently gained more interest. The present review focuses on the transition from compensatory LV hypertrophy (H) to LV dysfunction and the biomarkers associated with myocardial wall stress, fibrosis, and myocyte death. Moreover, we discuss the potential impact of non-invasive imaging parameters for optimizing the timing of aortic valve replacement and provide insight into novel biomarkers for possible prognostic use in AS. However, data from randomized clinical trials are necessary to define their utility in daily practice.https://www.mdpi.com/2218-273X/13/11/1661aortic stenosismyocardial fibrosiscardiac biomarkersremodelingrisk assessment |
| spellingShingle | Anca Drăgan Anca Doina Mateescu Novel Biomarkers and Advanced Cardiac Imaging in Aortic Stenosis: Old and New Biomolecules aortic stenosis myocardial fibrosis cardiac biomarkers remodeling risk assessment |
| title | Novel Biomarkers and Advanced Cardiac Imaging in Aortic Stenosis: Old and New |
| title_full | Novel Biomarkers and Advanced Cardiac Imaging in Aortic Stenosis: Old and New |
| title_fullStr | Novel Biomarkers and Advanced Cardiac Imaging in Aortic Stenosis: Old and New |
| title_full_unstemmed | Novel Biomarkers and Advanced Cardiac Imaging in Aortic Stenosis: Old and New |
| title_short | Novel Biomarkers and Advanced Cardiac Imaging in Aortic Stenosis: Old and New |
| title_sort | novel biomarkers and advanced cardiac imaging in aortic stenosis old and new |
| topic | aortic stenosis myocardial fibrosis cardiac biomarkers remodeling risk assessment |
| url | https://www.mdpi.com/2218-273X/13/11/1661 |
| work_keys_str_mv | AT ancadragan novelbiomarkersandadvancedcardiacimaginginaorticstenosisoldandnew AT ancadoinamateescu novelbiomarkersandadvancedcardiacimaginginaorticstenosisoldandnew |